Free Trial
→ The 1934 playbook (From American Alternative) (Ad)tc pixel Free ARDS Stock Alerts

Aridis Pharmaceuticals (ARDS) Competitors

Aridis Pharmaceuticals logo
$0.0028 +0.00 (+1,300.00%)
As of 03:52 PM Eastern
Compare

ARDS vs. CARM, SCPS, TRVN, NAVB, and AMPE

Should you be buying Aridis Pharmaceuticals stock or one of its competitors? The main competitors of Aridis Pharmaceuticals include Carisma Therapeutics (CARM), Scopus BioPharma (SCPS), Trevena (TRVN), Navidea Biopharmaceuticals (NAVB), and Ampio Pharmaceuticals (AMPE). These companies are all part of the "pharmaceutical products" industry.

How does Aridis Pharmaceuticals compare to Carisma Therapeutics?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

Carisma Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 199,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Carisma Therapeutics is more favorable than Aridis Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aridis Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Carisma Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aridis Pharmaceuticals has a beta of 49.48, meaning that its share price is 4,848% more volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Carisma Therapeutics Neutral

Aridis Pharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Carisma Therapeutics -254.28%N/A -192.17%

Aridis Pharmaceuticals has higher earnings, but lower revenue than Carisma Therapeutics. Carisma Therapeutics is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.03
Carisma Therapeutics$10.77M0.00-$60.48M$0.730.00

Summary

Carisma Therapeutics beats Aridis Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.03

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Aridis Pharmaceuticals Neutral

Scopus BioPharma has a beta of -0.26, suggesting that its share price is 126% less volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 49.48, suggesting that its share price is 4,848% more volatile than the S&P 500.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Aridis Pharmaceuticals N/A N/A N/A

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Aridis Pharmaceuticals beats Scopus BioPharma on 3 of the 4 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Trevena?

Trevena (NASDAQ:TRVN) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, Trevena's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Trevena Neutral
Aridis Pharmaceuticals Neutral

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Aridis Pharmaceuticals N/A N/A N/A

Trevena has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 49.48, suggesting that its stock price is 4,848% more volatile than the S&P 500.

Aridis Pharmaceuticals has lower revenue, but higher earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.02-$40.29M-$47.04N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.03

13.6% of Trevena shares are owned by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 2.7% of Trevena shares are owned by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Aridis Pharmaceuticals beats Trevena on 6 of the 8 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Aridis Pharmaceuticals Neutral

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Aridis Pharmaceuticals N/A N/A N/A

Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 49.48, suggesting that its stock price is 4,848% more volatile than the S&P 500.

Navidea Biopharmaceuticals has higher revenue and earnings than Aridis Pharmaceuticals. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.03

Summary

Aridis Pharmaceuticals beats Navidea Biopharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Ampio Pharmaceuticals?

Ampio Pharmaceuticals (NYSE:AMPE) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.03

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Ampio Pharmaceuticals Neutral
Aridis Pharmaceuticals Neutral

Ampio Pharmaceuticals has a beta of 7.65, meaning that its share price is 665% more volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 49.48, meaning that its share price is 4,848% more volatile than the S&P 500.

Company Net Margins Return on Equity Return on Assets
Ampio PharmaceuticalsN/A N/A N/A
Aridis Pharmaceuticals N/A N/A N/A

5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Aridis Pharmaceuticals beats Ampio Pharmaceuticals on 5 of the 6 factors compared between the two stocks.

Get Aridis Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARDS vs. The Competition

Export
MetricAridis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$149K$892.88M$6.25B$11.87B
Dividend YieldN/A4.84%2.73%5.21%
P/E Ratio0.031.7229.0428.47
Price / SalesN/A120.50476.6160.94
Price / CashN/A20.0727.6236.52
Price / BookN/A7.609.676.67
Net Income-$30.37M-$4.80M$3.55B$332.53M
7 Day PerformanceN/A-0.02%1.70%2.01%
1 Month PerformanceN/A5.52%5.62%9.20%
1 Year PerformanceN/A30.99%34.42%39.59%

Aridis Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARDS
Aridis Pharmaceuticals
N/A$0.00
+1,300.0%		N/AN/A$149KN/A0.0330
CARM
Carisma Therapeutics
2.3313 of 5 stars		$0.00
-16.7%		$1.00
+199,900.0%		N/A$21K$10.77M0.0020
SCPS
Scopus BioPharma
N/A$0.00
flat		N/AN/A$17KN/AN/A9
TRVN
Trevena
N/A$0.01
flat		N/AN/A$11K$443KN/A40
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ARDS) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel